Contents

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Volume 4 - Number 2

Common and Uncommon Features of Rheumatoid Arthritis and Chronic Obstructive Pulmonary Disease: Clues to a Future Therapy

, 4(2): 85 - 92

E. Andreakos


DOI: 10.2174/1568005310404020085




Hyperferritinaemia Without Iron Overload: Pathogenic and Therapeutic Implications

, 4(2): 93 - 105

F. Bertola, D. Veneri, S. Bosio, P. Battaglia, A. Disperati and R. Schiavon


DOI: 10.2174/1568008043339893




Regulators of G Protein Signaling: Potential Drug Targets for Controlling Cardiovascular and Immune Function

, 4(2): 107 - 118

H. Cho, K. Harrison and J. H. Kehrl


DOI: 10.2174/1568005310404020107




The Pathobiology of Osteoarthritis and the Rationale for Using the Chondroitin Sulfate for its Treatment

, 4(2): 119 - 127

Nicola Volpi


DOI: 10.2174/1568005310404020119




Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill Patients

, 4(2): 129 - 139

Reiner Oberbeck


DOI: 10.2174/1568005310404020129




Treatment of Inflammatory and Paraproteinemic Neuropathies

, 4(2): 141 - 148

Salvatore Monaco, Emanuela Turri, Gianluigi Zanusso and Barbara Maistrello


DOI: 10.2174/1568005310404020141




Flt3 Ligand Bioactivity and Pharmacology in Neoplasia

, 4(2): 149 - 156

A. J. Reber, A. E. Ashour, S. N. Robinson, J. E. Talmadge and J. C. Solheim


DOI: 10.2174/1568005310404020149




Activins, Myostatin and Related TGF-β Family Members as Novel Therapeutic Targets for Endocrine, Metabolic and Immune Disorders

, 4(2): 157 - 166

Kunihiro Tsuchida


DOI: 10.2174/1568005310404020157




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science